RT Journal Article
SR Electronic
T1 Epidemiological trends of osteoarthritis at the global, regional, and national levels from 1990 to 2021, with a projection from 2021 to 2050
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.30.24309697
DO 10.1101/2024.06.30.24309697
A1 Qiao, Lichun
A1 Li, Miaoqian
A1 Deng, Feidan
A1 Wen, Xinyue
A1 Wang, Jun
A1 Deng, Huan
A1 Xue, Zhaowei
A1 Wan, Ping
A1 Xiang, Rongqi
A1 Xie, Yanjun
A1 He, Huifang
A1 Fan, Xiangyu
A1 Song, Yufei
A1 Han, Jing
YR 2024
UL http://medrxiv.org/content/early/2024/06/30/2024.06.30.24309697.abstract
AB Objectives Osteoarthritis (OA) and has become a global public health problem. The purpose of this study was to elucidate the burden of OA across different geographic regions, ages, sexes, and types.Methods Publicly available data from the Global Burden of Disease 2021 were used in this study. The burden of OA was estimated at the global, SDI quintile, regional, and national levels from 1990 to 2021 through systematic analyses. Bayesian age-period-cohort models were utilized to predict the burden over the next 30 years.Results Globally, there were 607 million people suffering from OA with 46.6 million new cases and 21.3 million DALYs in 2021. The age-standardized incidence, prevalence and DALYs rates increased to 535.00, 6967.29, and 244.50 per 100,000 population, with knee OA accounting for more than 56%. The age-standardized rates of OA were higher in females than in males. East Asia, South Asia, and Western Europe were the top three regions and China, India, and the United States were the top three countries with the highest burdens. In addition, high body-mass index (BMI) resulted in 4.43 million DALYs with an increase of 205.10%. BAPC projections showed that the burden of OA will continue to rise over the next 30 years.Conclusions As populations ageing and global obesity rates rise, the burden of total OA and OA due to high BMI will continue to increase. Females and middle-aged and elderly patients are the current populations to focus on. The development and implementation of effective prevention and treatment strategies is critical.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (No.81872567).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used for the analyses are publicly available from http://ghdx.healthdata.org/gbd-results-tool.